On September 17, ARK Genomic Revolution ETF rose 8.15% in regular trading, trading at $51.775/share, with turnover of $171 million. The surge was driven by broad-based strength among the fund's genomics and AI healthcare holdings.
Key holding Tempus AI surged over 9% on the day, buoyed by a series of recent catalysts including its announcement to build the world's largest multimodal whole-genome dataset featuring 100,000 whole genome sequences paired with longitudinal clinical data, with a long-term goal of reaching 1 million genomes. Tempus AI also recently secured up to $9.5 million in ARPA-H funding for an autonomous cardiology AI agent, and obtained FDA clearance for its AI-enabled pulmonary hypertension detection device. Multiple brokerages initiated or upgraded coverage, with Piper Sandler upgrading to Overweight and raising its target to $76.
Other genomics sector names contributed to the rally, with 10x Genomics rising over 5% after announcing an AI pathology platform integration with Lunit, and Twist Bioscience gaining on strong AI pharma order momentum. The life sciences tools sector showed broadly active performance.
ARKG is an actively managed ETF that seeks long-term growth of capital by investing primarily in domestic and foreign equity securities of companies across multiple sectors relevant to the genomics revolution, including health care, information technology, materials, energy, and consumer discretionary.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments